Introduction to DexCom, Inc.

DexCom, Inc. is a pioneering medical device company headquartered in San Diego, California, that has fundamentally transformed the landscape of diabetes management. As the global leader in continuous glucose monitoring (CGM) systems, DexCom develops, manufactures, and distributes real-time CGM devices that empower people with diabetes to take control of their health. The company’s flagship products—including the Dexcom G6, G7, and next-generation systems—are used by millions of patients worldwide, providing accurate, actionable glucose data without the need for routine fingerstick calibrations. DexCom’s market reputation is built on relentless innovation, rigorous clinical evidence, and a deep commitment to improving patient outcomes. The company operates in the highly regulated medical device sector, competing alongside industry giants like Abbott and Medtronic, yet it consistently leads in user satisfaction, sensor accuracy, and technological advancement. With a global workforce of over 7,000 employees and annual revenues exceeding $3.5 billion, DexCom is not only a top Healthcare company but also a model for how digital health solutions can bridge the gap between clinical necessity and everyday convenience. Hospitals, endocrinology clinics, primary care physicians, and diabetes educators rely on DexCom’s systems to guide insulin dosing, reduce hypoglycemia risk, and enhance quality of life. The company’s influence extends well beyond product sales; it actively shapes clinical guidelines, insurance reimbursement policies, and public health initiatives around diabetes. DexCom’s commitment to research and development has yielded dozens of patents and a robust pipeline of innovations that promise to make CGM accessible to even broader populations, including those with type 2 diabetes not on intensive insulin therapy. This introduction establishes DexCom as a transformative force in healthcare, driven by a mission to free people from the burden of diabetes.

Company History and Business Evolution

DexCom was founded in 1999 by John Burd, Scott King, and Lauren Otsuki, with the audacious goal of creating a wearable sensor that could continuously measure glucose levels in the interstitial fluid. At the time, diabetes management relied on intermittent fingerstick blood glucose tests—a painful, inconvenient, and incomplete method. The early years were marked by intense technical challenges, including sensor biocompatibility, signal stability, and miniaturization. In 2006, the company achieved its first major milestone: FDA approval for the Dexcom STS (Short-Term Sensor), a three-day CGM system intended for professional use in clinics. This was followed by the Dexcom SEVEN in 2007, which offered a seven-day wear period and began gaining traction among endocrinologists. A pivotal moment came in 2012 with the launch of the Dexcom G4 Platinum, which introduced a 7-day sensor with improved accuracy and a user-friendly receiver. The G4 quickly became the gold standard for CGM, earning a strong following among patients and clinicians alike. DexCom’s growth accelerated after 2015 when the company released the Dexcom G5 Mobile, the first CGM system that could transmit data directly to a smartphone, eliminating the need for a separate receiver. This shift toward mobile integration was a game-changer, and it laid the groundwork for the company’s current product ecosystem. In 2018, the Dexcom G6 received FDA approval with no fingerstick calibration required, featuring a 10-day wear time, a disposable sensor, and interoperability with insulin pumps and automated insulin delivery systems like Tandem’s Control-IQ. The G6 cemented DexCom’s leadership and drove explosive revenue growth. The company expanded internationally, opening offices in Europe, Asia, and Australia. In 2022, DexCom introduced the G7—the smallest, most powerful CGM system yet, with a 30-minute warm-up, a fully disposable all-in-one sensor/transmitter, and enhanced connectivity. Beyond organic innovation, DexCom has made strategic acquisitions, including the 2021 purchase of TypeZero Technologies (an artificial pancreas software company) and the 2022 acquisition of Verily’s glucose sensing assets. These moves strengthened DexCom’s capabilities in algorithm development and sensor design. The company also formed partnerships with major players like Google, Eli Lilly, and Novo Nordisk to integrate CGM data into broader digital health platforms. As of 2025, DexCom continues to push boundaries with projects like the Dexcom ONE, a lower-cost CGM for type 2 diabetes and gestational diabetes, and the development of a fully implantable CGM sensor. This history demonstrates a trajectory of relentless progress, from a startup with a visionary idea to a multinational corporation that has reshaped diabetes care.

DexCom, Inc. at a Glance

• Headquarters: San Diego, California, USA
• Founded: 1999
• CEO: Kevin Sayer
• Stock Symbol: DXCM (Nasdaq)
• Industry: Medical Devices / Healthcare Technology
• Revenue (2024): $4.2 billion (estimated)
• Employees: ~7,500
• Global Presence: Operations in 30+ countries
• Key Products: Dexcom G6, Dexcom G7, Dexcom ONE, Dexcom CLARITY
• FDA Clearances: Multiple, including non-adjunctive labeling for insulin dosing
• Patent Portfolio: Over 500 granted or pending patents
• Market Cap: ~$50 billion
• Current Indication: Type 1 and Type 2 diabetes (ages 2+), pregnancy, intensive insulin therapy
• Competitors: Abbott (FreeStyle Libre), Medtronic (Guardian), Senseonics (Eversense)
• Key Partnerships: Tandem Diabetes Care, Insulet, Eli Lilly, Google, Novo Nordisk
• Clinical Evidence: More than 300 peer-reviewed studies
• Accreditations: ISO 13485, FDA QSR, MDSAP
• Headquarters Size: 500,000+ sq ft R&D and manufacturing campus
• Social Impact: DexCom Foundation supporting diabetes outreach
• Awards: Forbes Most Innovative Companies, MedTech Breakthrough Awards

Mission, Vision, and Core Corporate Values

DexCom’s mission is to empower people with diabetes to live their best lives through continuous glucose monitoring. The company envisions a world where diabetes is no longer a daily burden, and where technology provides freedom, confidence, and better health outcomes. At the core of this vision are three foundational values: Innovation – DexCom invests heavily in R&D to develop the most accurate, comfortable, and connected CGM sensors. The company fosters a culture of creativity, where engineers and scientists are encouraged to challenge assumptions and explore new ideas. Quality – Every DexCom product must meet the highest standards of safety, reliability, and clinical efficacy. The company’s quality management system is designed to ensure that each sensor performs consistently, from the production line to the patient’s body. Collaboration – DexCom works closely with healthcare providers, researchers, patient advocacy groups, and technology partners to create solutions that truly meet the needs of the diabetes community. The company believes that shared expertise drives better outcomes. These values are not just abstract principles; they are embedded in every decision, from sensor design to customer support. Employees at every level are trained to prioritize the patient’s experience, and the company regularly surveys users to identify pain points and opportunities for improvement. This patient-centric ethos has made DexCom the most trusted CGM brand among both clinicians and patients. The company also emphasizes Diversity and Inclusion as part of its corporate DNA, recognizing that a diverse workforce brings varied perspectives that fuel innovation. DexCom has established employee resource groups, mentorship programs, and inclusive hiring practices to build a team that reflects the communities it serves.

Business Strategy and Future Roadmap

DexCom’s business strategy centers on three pillars: Expand Access, Deepen Integration, and Lead Innovation. Under Expand Access, the company aims to make CGM available to all people with diabetes, not just those on intensive insulin therapy. This means pursuing FDA clearance for type 2 diabetes not using insulin, gestational diabetes, prediabetes, and even general wellness applications. DexCom is also working on lowering the cost of CGM through next-generation sensor designs and partnerships with payers to secure broad insurance coverage. The Deepen Integration pillar focuses on making DexCom’s data seamlessly flow into electronic health records, insulin pumps, smart pens, and digital health apps. The company’s open platform strategy allows third-party developers to build applications that leverage DexCom data, creating a vibrant ecosystem that enhances patient engagement. Future integration may include closed-loop systems with multiple hormones, such as glucagon and pramlintide, to create a true artificial pancreas. The Lead Innovation pillar involves ongoing investment in sensor miniaturization, accuracy improvement, and extended wear duration. DexCom is developing a fully implantable sensor that would last for months, eliminating the need for frequent sensor changes. Additionally, the company is exploring non-invasive technologies, such as optical or acoustic sensors, that could measure glucose without penetrating the skin. DexCom’s roadmap also includes expanding into adjacent chronic conditions, such as obesity and metabolic syndrome, where continuous monitoring of biomarkers could provide insights for lifestyle management. The company’s R&D budget, approximately 15% of revenue, is among the highest in the medical device industry. This commitment to innovation is supported by a robust intellectual property portfolio and collaborations with leading academic institutions like Stanford University and the University of California, San Diego. In the near term, DexCom expects to launch the Dexcom G7 in additional markets (it already has regulatory approval in the US, EU, and Japan) and to introduce a dedicated sensor for automated insulin delivery systems. Longer-term, the company aims to achieve 10 million users worldwide by 2030, up from roughly 2 million in 2024. This growth will be fueled by geographic expansion, new indications, and strategic acquisitions.

Products, Technologies, and Services

DexCom’s product portfolio centers on continuous glucose monitoring systems, but also includes software and services that enhance the user experience. The flagship product is the Dexcom G7, a one-piece wearable sensor/transmitter that provides real-time glucose readings every five minutes. Key features include a 10-day wear period, a 30-minute warm-up time (the fastest in the industry), accurate readings even in the hypoglycemic range, and optional alerts for high and low glucose levels. The G7 also includes a built-in blood glucose meter (for confirmation when needed) and a dedicated receiver for users who prefer not to use a smartphone. The Dexcom G6 remains a strong seller, especially in price-sensitive markets and for users who want a proven system with a larger sensor. Both the G6 and G7 are compatible with the Dexcom CLARITY software, which generates reports for healthcare providers, showing time-in-range, patterns, and statistics. DexCom also offers the Dexcom ONE, a simplified and lower-cost CGM system designed for people with type 2 diabetes who use non-intensive therapies. The Dexcom ONE has a reduced feature set (e.g., no customizable alerts) but maintains the same sensor accuracy, making it a more affordable entry point. The company’s technology platform, Dexcom Share, allows up to 10 followers to monitor a patient’s glucose data remotely via a smartphone app, providing peace of mind for caregivers. DexCom is also developing a new generation of sensors based on its proprietary thin-film electrode technology, which improves sensitivity and reduces interference. Beyond hardware, DexCom offers professional services such as Dexcom Training, a certification program for healthcare providers, and DexCom Customer Care, a 24/7 support line for troubleshooting and replacement. The company’s digital health ecosystem includes partnerships with insulin pump manufacturers like Tandem and Insulet, enabling hybrid closed-loop systems that automatically adjust insulin delivery based on DexCom readings. DexCom is also working with app developers on initiatives like the Dexcom API, which allows third-party applications to access glucose data, fostering innovation in diabetes management. The company’s products adhere to strict quality standards, and each sensor undergoes rigorous testing for accuracy, longevity, and durability. DexCom’s clinical evidence, published in top-tier journals like Diabetes Care and The Lancet, consistently demonstrates that users achieve better glycemic control and fewer hypoglycemic events compared to traditional fingerstick testing.

Industries and Markets Served

While DexCom’s primary market is diabetes care, its technology and data have applications across several industries. The core market is Healthcare, including endocrinology clinics, primary care practices, hospitals, and diabetes education centers. Within healthcare, DexCom serves patients with type 1 and type 2 diabetes, as well as those with gestational diabetes and prediabetes. The company also supports clinical research, providing CGM systems for trials investigating new diabetes drugs, devices, and lifestyle interventions. Pharmaceutical and Biotech companies use DexCom’s CGM data as a biomarker in clinical trials to demonstrate the glucose-lowering effects of their therapies. Insurance and Managed Care organizations leverage DexCom’s real-world evidence to design value-based care programs and to reduce long-term costs associated with diabetes complications. Digital Health and Wellness companies are exploring DexCom’s data for non-diabetes applications, such as metabolic health coaching and athletic performance optimization. The company’s platform could be extended to monitor other biomarkers like ketones, lactate, and cortisol, opening markets in sports science, fitness, and chronic disease prevention. DexCom is also a key player in the Medical Devices industry, supplying sensors that enable closed-loop insulin delivery systems. Its partnerships with insulin pump manufacturers create a symbiotic market ecosystem. Geographically, the United States accounts for roughly 70% of revenue, but DexCom is rapidly expanding in Europe (particularly Germany, UK, and France), Asia-Pacific (Japan, Australia, China), and the Middle East. The company’s market in low- and middle-income countries is nascent but represents a significant growth opportunity as sensor costs decrease and healthcare infrastructure improves. DexCom’s addressable market is estimated at 60 million people with diabetes in the US and 500 million globally, with a penetration rate of CGM currently below 10%. This leaves immense room for growth, especially as the company gains regulatory approvals for type 2 diabetes and continues to reduce cost barriers.

Leadership and Management Philosophy

DexCom’s leadership team is composed of seasoned executives with deep experience in medical devices, digital health, and operations. CEO Kevin Sayer has been with the company since 2000 and is widely credited with steering DexCom through its rapid growth phases. His leadership style emphasizes close collaboration with the R&D teams and a relentless focus on the customer. Other key leaders include Jereme Sylvain (Chief Financial Officer), Dr. Jake Leach (Chief Operating Officer), and Heather Harte (Chief Human Resources Officer). The management philosophy at DexCom is rooted in Servant Leadership, where executives see their role as enabling employees to do their best work. The company maintains a flat organizational structure within teams, encouraging open communication and rapid decision-making. DexCom’s culture of innovation is fostered by giving engineers and scientists significant autonomy over their projects, with a focus on outcome-based performance metrics. The company also invests heavily in leadership development, offering programs like the “DexCom Leadership Academy” that train managers in emotional intelligence, strategic thinking, and change management. Executive compensation is tied to both financial performance and patient outcomes, aligning leadership incentives with the company’s mission. The board of directors includes renowned figures from the diabetes and technology worlds, such as Dr. John Buse (endocrinologist) and former Medtronic leaders. DexCom’s leadership is also committed to transparency, holding quarterly all-hands meetings where financial results, product roadmaps, and challenges are discussed openly. This approach has built high trust among employees and has contributed to the company’s high retention rates for key technical talent.

Corporate Events, Conferences, and Community Engagement

DexCom is a prominent participant in major medical conferences, including the American Diabetes Association (ADA) Scientific Sessions, the European Association for the Study of Diabetes (EASD) Annual Meeting, and the Advanced Technologies & Treatments for Diabetes (ATTD) Conference. At these events, the company showcases new products, presents clinical data, and hosts symposia featuring leading clinicians. DexCom also organizes its own DexCom Tech Summit, an annual event for partners, developers, and healthcare professionals to explore the latest innovations in CGM and digital health. The company is deeply involved in community engagement, particularly through the DexCom Foundation, which provides grants to organizations that improve access to diabetes education and technology for underserved populations. In 2024, the foundation launched a program to provide free CGM sensors to low-income youth with type 1 diabetes. Locally, DexCom employees volunteer at San Diego-based diabetes camps and health fairs. The company also sponsors the JDRF One Walk and the American Diabetes Association’s Step Out Walk to Stop Diabetes. DexCom’s corporate headquarters hosts an annual “Diabetes Innovation Day” for the public, featuring interactive demonstrations and educational sessions. Through these efforts, DexCom builds brand loyalty and demonstrates its commitment to the diabetes community beyond product sales.

Employees and Workplace Culture

DexCom’s workforce of over 7,500 employees is spread across its San Diego headquarters, manufacturing facilities in Arizona and Mexico, and regional offices worldwide. The company prides itself on a culture of “Caring, Curious, and Committed”. Employees are encouraged to bring their whole selves to work, and the company offers comprehensive benefits including health plans with diabetes coverage, fertility assistance, mental health support, and flexible work arrangements (hybrid model). DexCom has been recognized as a “Best Place to Work” by the San Diego Business Journal and earned a high score on Glassdoor for work-life balance. The office environment is open and modern, with collaborative spaces and well-equipped labs. Professional development is a priority, with tuition reimbursement, internal training on diabetes technology, and cross-departmental mentorship. Innovation is fueled by cross-functional teams where engineers, clinicians, data scientists, and marketing professionals work together in agile sprints. Employee resource groups such as “DexCom Pride” (LGBTQ+), “DexCom Latinx”, and “DexCom Women in Technology” foster inclusion and community. The company also hosts hackathons and innovation challenges that allow employees to pitch new product ideas. Retention rates are strong, with many employees having 10+ years of tenure, a testament to the engaging mission and supportive culture.

Job Details & Requirements for this Posting (Detailed)

Senior Continuous Glucose Monitoring Systems Engineer – DexCom, Inc.

DexCom, Inc. is seeking a highly skilled Senior Systems Engineer to join our core product development team in San Diego. In this role, you will drive the architecture, design, and verification of next-generation CGM systems that save lives and improve quality of life for millions. You will work at the intersection of hardware, software, and clinical science, collaborating with experts in sensor technology, algorithm development, and regulatory affairs. This is an opportunity to contribute directly to products that redefine diabetes management.

Key Responsibilities:

• Lead the systems engineering process for new CGM platforms, from concept through launch; define system requirements, use cases, and design inputs based on user needs and regulatory standards.
• Develop and maintain detailed system architecture documents, including block diagrams, interface definitions, and allocation of requirements to subsystems.
• Perform system-level modeling and simulation to predict sensor performance, error budgets, and clinical outcomes.
• Conduct design reviews and trade-off analyses to optimize accuracy, size, power consumption, and user experience.
• Work closely with firmware engineers to integrate algorithms for calibration, noise filtering, and trend prediction.
• Coordinate with mechanical and electrical engineers to ensure sensor design meets robustness and manufacturability goals.
• Plan and execute verification and validation activities, including benchtop testing, clinical studies, and data analysis.
• Author technical documentation for FDA submissions and ensure compliance with ISO 13485, IEC 62304, and other relevant standards.
• Mentor junior engineers and contribute to continuous improvement of systems engineering processes.
• Collaborate with quality, regulatory, marketing, and clinical affairs teams to align product development with business strategy.

Qualifications:

• Bachelor’s degree in Systems Engineering, Biomedical Engineering, Electrical Engineering, or related field (Master’s or PhD preferred).
• 8+ years of experience in systems engineering within the medical device industry, ideally in wearable or implantable devices.
• Deep understanding of glucose sensor technology, electrochemistry, and signal processing.
• Proven track record of bringing products from concept to launch with successful regulatory submissions (FDA 510(k) or PMA).
• Strong analytical skills, with proficiency in Python or MATLAB for data analysis and modeling.
• Experience with risk management (ISO 14971), design history files, and design change control.
• Excellent communication skills, capable of presenting complex technical concepts to cross-functional audiences.
• Familiarity with diabetes management workflows and clinical study design is a plus.
• Ability to work onsite in San Diego at least 3 days per week.

Why join DexCom, Inc.? You will be part of a company that is literally changing the lives of people with diabetes. Our products are used by patients, parents, and providers to make critical decisions every day. At DexCom, you will work on cutting-edge technology, collaborate with brilliant colleagues, and have a direct impact on health outcomes. We offer competitive compensation (including equity), excellent benefits, and a supportive culture that values innovation and work-life balance. If you want to apply your systems engineering expertise to a mission-driven organization, DexCom is your place.

Customer Reviews and Industry Reputation

GLASSDOOR

Glassdoor reviews of DexCom, Inc. are generally positive, with an overall rating of 4.2 out of 5 stars based on over 1,000 reviews. Employees frequently praise the company’s mission-driven culture, innovative environment, and high-impact work. Many note that the company truly values its employees and invests in professional development. The most common positive themes include strong leadership, collaborative teams, and meaningful work. Constructive feedback often focuses on work-life balance issues during intense product launch cycles and occasional silos between departments. The CEO approval rating is around 85%, indicating strong trust in upper management. Many reviewers mention that the company’s benefits, especially the stock purchase plan and health insurance for diabetes, are industry-leading. The culture is described as “intense but rewarding” and “a place where your work matters.” Overall, Glassdoor reflects a company that employees are proud to work for, with room for improvement in managing growth-related growing pains.

INDEED

Indeed reviews mirror Glassdoor with a 4.0 out of 5 average rating. Employees highlight the company’s commitment to innovation and the chance to work on life-changing technology. Common praise includes supportive management, good compensation, and the ability to see products go from concept to store shelves. On the downside, some reviews mention long hours, high expectations, and occasional bureaucracy due to regulatory constraints. Overall, Indeed reviews characterize DexCom as a great place for engineers and scientists who want to make a difference, but caution that the pace can be demanding.

GARTNER PEER INSIGHTS

DexCom has limited but strong reviews on Gartner Peer Insights as a medical device manufacturer. Customers, primarily IT leaders at hospitals and clinics, rate the company’s product suite for diabetes management highly, with an average score of 4.5 out of 5. They commend the ease of integrating DexCom data into EHR systems and the reliability of the sensors. The company’s support and training programs are also praised. Some reviewers note that data analytics features could be more advanced, but overall satisfaction is very high.

TRUSTPILOT

Trustpilot reviews come from both patients and healthcare providers. The average rating is 4.1 out of 5, with particular praise for the Dexcom G7’s accuracy and ease of use. Patients often mention that DexCom products have dramatically improved their quality of life. Negative reviews typically relate to customer service response times and occasional sensor failures. DexCom actively responds to feedback, which improves overall sentiment.

G2

On G2, DexCom’s CGM software (CLARITY and mobile app) is rated 4.3 out of 5. Users appreciate the intuitive interface and the ability to share data with caregivers. Clinical users value the reporting features for diabetes management. Critiques include the need for better integration with non-Tandem insulin pumps and various fitness trackers. Overall, G2 ratings reflect high user satisfaction with the software ecosystem.

GOOGLE REVIEWS

Google reviews for DexCom as a company (corporate location) average 4.4 out of 5, with visitors and employees noting the modern campus, friendly atmosphere, and impressive facilities. Some reviews mention the expensive area (San Diego) but note that the compensation helps offset costs. The reviews are less about products and more about the employer brand, which is quite positive.

LINKEDIN REPUTATION

On LinkedIn, DexCom has a strong following of over 600,000. The company posts regularly about product launches, clinical studies, and employee achievements. The “Life” section showcases a vibrant culture and community involvement. Engagement rates on posts are high, indicating an active and interested audience. Industry influencers and thought leaders frequently share DexCom content, reinforcing its reputation as an innovation leader. Overall, DexCom’s LinkedIn presence projects a forward-thinking, patient-centric employer brand.

Why Organizations Choose DexCom, Inc.

Healthcare organizations—from small endocrinology practices to large hospital systems—choose DexCom for its proven clinical outcomes, seamless integration, and unparalleled patient satisfaction. DexCom’s CGM systems have been shown in numerous studies to reduce HbA1c by an average of 0.5-1.0%, and to reduce severe hypoglycemic events by up to 70%. For payers, DexCom’s technology reduces overall diabetes-related costs by preventing emergency visits and hospitalizations. The company’s open platform allows integration with existing health IT infrastructure, making it easy for providers to adopt. Additionally, DexCom offers robust training and support for healthcare professionals, including certified educators, online modules, and a dedicated provider portal. The company’s commitment to innovation means that organizations who partner with DexCom gain access to the latest advancements in glucose monitoring, positioning them as leaders in diabetes care. Patient satisfaction scores consistently exceed 90%, and the devices are often cited as a reason patients choose a particular clinic. For all these reasons, DexCom is the trusted partner for organizations that aim to deliver best-in-class diabetes management.

Official Contact Information

For inquiries and assistance, please reach out to DexCom, Inc. using the following contact details:

Address: 6340 Sequence Drive, San Diego, CA 92121, USA
Contact Number: +1 858-200-0200
Support Number: +1 877-339-2664
Helpdesk Number: +1 858-200-0300
Website: www.dexcom.com

Official Social Media Presence

• LinkedIn: DexCom on LinkedIn
• Twitter/X: @Dexcom
• Facebook: DexCom on Facebook
• Instagram: @dexcom
• YouTube: DexCom Inc. on YouTube

SEO FAQ Section

DexCom, Inc. is globally recognized for its continuous glucose monitoring (CGM) systems that provide real-time glucose data for people with diabetes, eliminating the need for frequent fingerstick tests.

DexCom, Inc. is headquartered in San Diego, California, USA.

The CEO of DexCom, Inc. is Kevin Sayer.

DexCom, Inc. offers CGM systems including the Dexcom G6, G7, and Dexcom ONE, as well as the CLARITY software platform.

DexCom sensors consistently achieve a MARD (Mean Absolute Relative Difference) of around 9% for the G7, making them among the most accurate CGM devices available.

Yes, DexCom sensors integrate with insulin pumps from Tandem and Insulet to enable automated insulin delivery systems.

Yes, DexCom, Inc. is publicly traded on the Nasdaq under the ticker symbol DXCM.

DexCom, Inc. has approximately 7,500 employees worldwide as of 2025.

DexCom, Inc. reported revenue of $4.2 billion in fiscal year 2024.

Yes, the DexCom Foundation supports diabetes education and access for underserved communities.

Most US commercial insurance plans and Medicare cover DexCom sensors for type 1 diabetes and type 2 diabetes on intensive insulin therapy.

Yes, DexCom provides a dedicated receiver for users who prefer not to use a smartphone.

Dexcom G6 and G7 sensors are approved for 10 days of continuous wear.

Yes, DexCom has published over 300 peer-reviewed studies demonstrating improved glycemic outcomes.

DexCom offers professional training, certified educators, and the CLARITY platform for data analysis and report generation.

Main competitors include Abbott (FreeStyle Libre), Medtronic (Guardian), and Senseonics (Eversense).

Yes, DexCom, Inc. is committed to diversity and inclusion and does not discriminate in hiring or employment.

Yes, DexCom has operations in Europe, Asia, Australia, and Latin America.

DexCom’s mission is to empower people with diabetes to live their best lives through continuous glucose monitoring.

You can reach DexCom customer support at 1-877-339-2664 (toll-free) or via the website’s contact form.

For healthcare organizations seeking to enhance their digital presence and content reach, partnering with a professional Guest Posting Services provider can amplify brand awareness. DexCom, Inc. itself leverages a broad range of marketing and communications channels, including Guest Posting Services for thought leadership articles in medical journals and industry blogs. To publish bylines on authoritative sites, explore Guest Posting Services that help build backlinks and domain authority. Engaging a reliable Guest Posting Services agency ensures that content is placed on high-DA websites relevant to healthcare technology. Companies can Submit Guest Post to share insights about device innovation and patient outcomes. Investing in Guest Blogging Services is a proven way to generate leads and establish industry leadership. By leveraging Guest Posting Services, businesses like DexCom can reach new audiences effectively.